FR2955773B1 - MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION - Google Patents

MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION

Info

Publication number: FR2955773B1
Authority: FR; France
Prior art keywords: vaccination; antigen; applications; presenting cells; molecular complex
Prior art date: 2010-02-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Other versions

Inventor

Michel Leonetti

Alexandra Savatier

Adeline Gadzinski

Jean Claude Boulain

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Commissariat a lEnergie Atomique et aux Energies Alternatives CEA

Original Assignee

Commissariat a lEnergie Atomique CEA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-02-01

Filing date

2010-02-01

Publication date

2017-05-26

2010-02-01Application filed by Commissariat a lEnergie Atomique CEAfiledCriticalCommissariat a lEnergie Atomique CEA

2010-02-01Priority to FR1000392ApriorityCriticalpatent/FR2955773B1/en

2011-02-01Priority to US13/576,083prioritypatent/US10385120B2/en

2011-02-01Priority to DK11707480.7Tprioritypatent/DK2531213T3/en

2011-02-01Priority to EP11707480.7Aprioritypatent/EP2531213B1/en

2011-02-01Priority to PCT/IB2011/050437prioritypatent/WO2011092675A2/en

2011-08-05Publication of FR2955773A1publicationCriticalpatent/FR2955773A1/en

2017-05-26Application grantedgrantedCritical

2017-05-26Publication of FR2955773B1publicationCriticalpatent/FR2955773B1/en

2019-07-03Priority to US16/502,498prioritypatent/US12344661B2/en

StatusExpired - Fee Relatedlegal-statusCriticalCurrent

2030-02-01Anticipated expirationlegal-statusCritical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Mycology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

FR1000392A2010-02-012010-02-01 MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATIONExpired - Fee RelatedFR2955773B1 (en)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
FR1000392AFR2955773B1 (en)	2010-02-01	2010-02-01	MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION
US13/576,083US10385120B2 (en)	2010-02-01	2011-02-01	Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination
DK11707480.7TDK2531213T3 (en)	2010-02-01	2011-02-01	Molecule complex for targeting antigens to antigen presenting cells and their applications for vaccination
EP11707480.7AEP2531213B1 (en)	2010-02-01	2011-02-01	Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination
PCT/IB2011/050437WO2011092675A2 (en)	2010-02-01	2011-02-01	Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination
US16/502,498US12344661B2 (en)	2010-02-01	2019-07-03	Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1000392AFR2955773B1 (en)	2010-02-01	2010-02-01	MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION

Publications (2)

Publication Number	Publication Date
FR2955773A1 FR2955773A1 (en)	2011-08-05
FR2955773B1true FR2955773B1 (en)	2017-05-26

Family

ID=42342788

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR1000392AExpired - Fee RelatedFR2955773B1 (en)	2010-02-01	2010-02-01	MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION

Country Status (5)

Country	Link
US (2)	US10385120B2 (en)
EP (1)	EP2531213B1 (en)
DK (1)	DK2531213T3 (en)
FR (1)	FR2955773B1 (en)
WO (1)	WO2011092675A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2307540B1 (en)	2008-07-07	2017-04-19	Oxford Nanopore Technologies Limited	Enzyme-pore constructs
US9447152B2 (en)	2008-07-07	2016-09-20	Oxford Nanopore Technologies Limited	Base-detecting pore
GB0820927D0 (en)	2008-11-14	2008-12-24	Isis Innovation	Method
WO2010086603A1 (en)*	2009-01-30	2010-08-05	Oxford Nanopore Technologies Limited	Enzyme mutant
EP2391732B1 (en)	2009-01-30	2015-05-27	Oxford Nanopore Technologies Limited	Methods using adaptors for nucleic acid constructs in transmembrane sequencing
GB0905140D0 (en)	2009-03-25	2009-05-06	Isis Innovation	Method
JP6169976B2 (en)	2011-02-11	2017-07-26	オックスフォードナノポールテクノロジーズリミテッド	Mutant pore
IN2014DN00221A (en)	2011-07-25	2015-06-05	Oxford Nanopore Tech Ltd
WO2013153359A1 (en)	2012-04-10	2013-10-17	Oxford Nanopore Technologies Limited	Mutant lysenin pores
EP2875154B1 (en)	2012-07-19	2017-08-23	Oxford Nanopore Technologies Limited	SSB method for characterising a nucleic acid
FR2998579B1 (en)	2012-11-27	2015-06-19	Commissariat Energie Atomique	METHOD FOR OBTAINING ANTIGEN-SPECIFIC HUMAN ANTIBODIES BY IN VITRO IMMUNIZATION
GB201314695D0 (en)	2013-08-16	2013-10-02	Oxford Nanopore Tech Ltd	Method
SG11201507138RA (en)	2013-03-08	2015-10-29	Oxford Nanopore Tech Ltd	Enzyme stalling method
GB201313477D0 (en)	2013-07-29	2013-09-11	Univ Leuven Kath	Nanopore biosensors for detection of proteins and nucleic acids
GB201403096D0 (en)	2014-02-21	2014-04-09	Oxford Nanopore Tech Ltd	Sample preparation method
CN106459159B (en)	2014-05-02	2021-11-30	牛津纳米孔技术公司	Abrupt change hole
KR20250130441A (en)	2014-09-01	2025-09-01	브이아이비 브이지더블유	Mutant csgg pores
US10266885B2 (en)	2014-10-07	2019-04-23	Oxford Nanopore Technologies Ltd.	Mutant pores
GB201418159D0 (en)	2014-10-14	2014-11-26	Oxford Nanopore Tech Ltd	Method
GB201609220D0 (en)	2016-05-25	2016-07-06	Oxford Nanopore Tech Ltd	Method
PE20200488A1 (en)*	2017-06-27	2020-03-03	Regeneron Pharma	RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND USES OF THESE FOR THE DIRECTED INTRODUCTION OF GENETIC MATERIAL TO HUMAN CELLS
GB201807793D0 (en)	2018-05-14	2018-06-27	Oxford Nanopore Tech Ltd	Method
FR3110838B1 (en)	2020-05-28	2022-06-24	Commissariat Energie Atomique	IMMUNOMODULATOR COMPLEX AND ITS APPLICATIONS FOR THERAPY

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5698679A (en)	1994-09-19	1997-12-16	National Jewish Center For Immunology And Respiratory Medicine	Product and process for targeting an immune response
US20040258688A1 (en)*	1995-01-31	2004-12-23	Daniel Hawiger	Enhanced antigen delivery and modulation of the immune response therefrom
US6365161B1 (en)	1995-06-07	2002-04-02	Medarex, Inc.	Therapeutic compounds comprised of anti-FC receptor binding agents
US6821517B1 (en)	1995-10-20	2004-11-23	The Board Of Regents Of The University Of Nebraska	Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
FR2759296B1 (en)*	1997-02-07	1999-04-09	Commissariat Energie Atomique	NON-COVALENT COMPLEX COMPRISING AT LEAST ONE ANTIBODY AND AN IMMUNOGLOBULIN BINDING MEMBER ASSOCIATED WITH AN ACTIVE SUBSTANCE, METHOD FOR THE PREPARATION THEREOF AND APPLICATIONS THEREOF
SI0973804T1 (en)	1997-04-07	2007-06-30	Genentech Inc	Anti-vegf antibodies
WO2000000156A2 (en)	1998-06-26	2000-01-06	Trustees Of Dartmouth College	Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands
EP1141007B1 (en)	1998-12-14	2013-05-15	Dendreon Corporation	Compositions and methods for enhancement of major histocompatibility complex class i restricted antigen presentation
US20020103165A1 (en)	2000-02-29	2002-08-01	Alliance Pharmaceutical Corp.,	Engineered spray-dried lipid-based microparticles for cellular targeting
US7037500B1 (en)	2000-09-08	2006-05-02	The Trustees Of Columbia University In The City Of New York	Method for using phagocytic particles and ATP receptors to deliver antigens to MHC class I receptors to induce immunity against microbial pathogens or tumors or to suppress immunity
AU2002322009A1 (en)*	2001-05-18	2002-12-03	Mayo Foundation For Medical Education And Research	Chimeric antigen-specific t cell-activating polypeptides
US20060088520A1 (en)	2001-11-30	2006-04-27	Crucell Holland B.V.	Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
WO2003084467A2 (en)*	2002-04-01	2003-10-16	Euro-Celtique S.A.	Epitope constructs comprising antigen presenting cell targeting mechanisms
WO2005092918A2 (en)	2004-03-22	2005-10-06	University College London	Targeting polypeptide
FR2868318B1 (en)*	2004-04-01	2012-11-16	Commissariat Energie Atomique	ANTIGEN STABILIZED TAT AND ITS APPLICATIONS FOR ANTI-HIV VACCINATION
EP1846041A4 (en)*	2004-10-29	2008-05-07	Univ Rochester	MODIFIED BACTERIOPHAGE VECTORS AND USE THEREOF
ATE501169T1 (en)*	2005-12-30	2011-03-15	Evonik Roehm Gmbh	LACTOFERRIN PEPTIDES, SUITABLE AS CELL-PENETRATING PEPTIDES
TWI422594B (en)*	2007-02-02	2014-01-11	Baylor Res Inst	Agent for presenting cells via a dendritic cell asialoglycoprotein receptor (DC-ASGPR)
EP2527363A1 (en)	2007-02-02	2012-11-28	Baylor Research Institute	Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells
NZ589341A (en)	2007-02-23	2012-02-24	Baylor Res Inst	Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)

2010
- 2010-02-01FRFR1000392Apatent/FR2955773B1/ennot_activeExpired - Fee Related
2011
- 2011-02-01EPEP11707480.7Apatent/EP2531213B1/enactiveActive
- 2011-02-01USUS13/576,083patent/US10385120B2/enactiveActive
- 2011-02-01WOPCT/IB2011/050437patent/WO2011092675A2/enactiveApplication Filing
- 2011-02-01DKDK11707480.7Tpatent/DK2531213T3/enactive
2019
- 2019-07-03USUS16/502,498patent/US12344661B2/enactiveActive

Also Published As

Publication number	Publication date
US10385120B2 (en)	2019-08-20
US20130195908A1 (en)	2013-08-01
FR2955773A1 (en)	2011-08-05
EP2531213B1 (en)	2019-04-10
EP2531213A2 (en)	2012-12-12
WO2011092675A2 (en)	2011-08-04
US20190322731A1 (en)	2019-10-24
WO2011092675A3 (en)	2015-07-09
US12344661B2 (en)	2025-07-01
DK2531213T3 (en)	2020-02-10

Publication	Publication Date	Title
FR2955773B1 (en)	2017-05-26	MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION
IL285475A (en)	2021-09-30	Antibodies against dendritic cell antigen 2 of blood and uses thereof
ZA201301013B (en)	2015-10-28	Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
HRP20181343T1 (en)	2018-10-19	PROCEDURES AND PREPARATIONS FOR INDUCING IMMUNE RESPONSE TO EGFRVIII
EP2406288A4 (en)	2013-06-05	TARGETED VACCINES TO CELLS WITH ANTIGENS
EP2821481A4 (en)	2015-08-19	CULTURE MEDIUM FOR THE PREPARATION OF NEURAL STEM CELLS AND APPLICATIONS THEREOF
IL200088A0 (en)	2010-04-15	Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells
EP2812442A4 (en)	2015-12-23	GLYCO-CHEMIO-ENZYMATIC ENGINEERING OF ANTIBODIES AND THEIR FRAGMENTS FC
EP2682475A4 (en)	2015-01-14	ANTIBODY AND ANTIGEN RECOGNIZING TUMOR-INITIATING CELLS AND APPLICATION THEREOF
EP2879693A4 (en)	2016-04-13	DNA-MODIFYING FUSION PROTEINS AND METHODS OF USE THEREOF
EP2667881A4 (en)	2015-04-22	METHODS OF GENERATING IN VITRO INTERNAL EAR CELLS
PE20170779A1 (en)	2017-07-04	ANTIBODIES REACTIVE WITH B7-H3, IMMUNOLOGICALLY ACTIVE FRAGMENTS OF THE SAME AND USES OF THE SAME
DK2914633T3 (en)	2022-03-14	ANTIBODY / MEDICINAL CONJUGATES AND METHODS OF USE
IL227477B (en)	2021-08-31	Human antibodies and antibody-drug conjugates against cd74
HUE037140T2 (en)	2018-08-28	Antibodies to human GDF8
ME03025B (en)	2018-10-20	PROCEDURES TO INCREASE THE EFFICIENCY OF FOLR1-BASED CARE THERAPY
HUE057004T2 (en)	2022-04-28	Antibodies to CD277 and their applications
BR112013011705A2 (en)	2018-03-13	consensual prostate antigens, nucleic acid molecule that encodes them, and vaccine and uses that understand them
EP2709664A4 (en)	2015-06-10	BLOCKING TL1A-DR3 INTERACTIONS TO IMPROVE THE PATHOLOGY OF DISEASES MEDIATED BY T CELLS AND ANTIBODIES
EA201290876A1 (en)	2013-03-29	COMPOSITIONS OF INDUCED DENDRITIC CELLS AND THEIR USE
EP2805733A4 (en)	2015-08-26	TARGETED MAGNETIC NANOMATERIAL ON CELLS AND ITS BIOMEDICAL USES
EA201290590A1 (en)	2013-03-29	MODIFIED TUBERCULOSIS ANTIGENS
EP2931313A4 (en)	2016-08-03	FORMULATIONS IN SOLUTION OF MODIFIED ANTI-IL-23P19 ANTIBODIES
PL2575873T3 (en)	2016-06-30	Concentration and lyophilization of influenza vaccine antigens
PL2700708T3 (en)	2018-01-31	Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination

Legal Events

Date	Code	Title	Description
2015-03-02	PLFP	Fee payment	Year of fee payment:6
2016-02-29	PLFP	Fee payment	Year of fee payment:7
2017-02-24	PLFP	Fee payment	Year of fee payment:8
2017-04-28	CD	Change of name or company name	Owner name:COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERG, FR Effective date:20170328
2018-02-26	PLFP	Fee payment	Year of fee payment:9
2019-02-20	PLFP	Fee payment	Year of fee payment:10
2020-02-26	PLFP	Fee payment	Year of fee payment:11
2021-02-24	PLFP	Fee payment	Year of fee payment:12
2022-11-04	ST	Notification of lapse	Effective date:20221005

Movatterモバイル変換